Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 2, 2016

View Archived Issues

Grant supports Atomo Diagnostics' development of next-generation HIV self-test solution

FDA grants orphan drug designation to napabucasin

Celgene Quanticel Research patents brodomain inhibitors

AbbVie discloses TNF-alpha modulators

Bayer Pharma describes HSKM-B inhibitors

Spyryx Biosciences presents in vitro and in vivo data for SPX-101

Symphogen initiates phase I/II study of Sym-013 in advanced epithelial malignancies

IURTC presents anti-HBV agents

First-in-human dose administered in phase I clinical study of VB-1953

Phase I trial explores safety and immunogenicity of ZPIV in healthy volunteers

Anti-alpha4beta7 MAb regimen leads to SIV suppression long after treatment in monkeys

Cempra receives milestone payment from Toyama Chemical

Flexion Therapeutics reports positive results from study of Zilretta in OA patients with diabetes

Pfizer discontinues bococizumab global development program

FDA and EMA accept Novartis' applications for ribociclib plus letrozole in advanced breast cancer

Mitsubishi Tanabe and Kolon Life Science sign licensing agreement for Invossa in Japan

ACADIA Pharmaceuticals initiates phase II SERENE study of pimavanserin

Epizyme enters cooperative research and development agreements with NCI's CTEP

MDNA collaborates with University of Oxford on blood-based test for endometriosis

Tesaro completes rolling NDA submission for niraparib

Allergan completes acquisition of Tobira Therapeutics

Celldex Therapeutics to acquire Kolltan Pharmaceuticals

Nimbus Therapeutics receives milestone payment from Gilead for ACC inhibitor program

NCI awards SBIR grant to RadioMedix and AREVA Med

ATAD5 may be a rare cancer predisposition gene for uveal melanoma

Bellicum Pharmaceuticals and OPBG to collaborate using Bellicum's molecular safety switch technology

Positive clinical trial results reported for enfortumab vedotin in urothelial cancer

Researchers identify a novel locus for atrial fibrillation at TTN

SK Chemical's NBP607-QIV effective in phase III influenza study

Janssen's JNJ-53718678 safe in phase I trial for RSV

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...